Merck is adjusting its development path for Winrevair (vericiguat/nearby class reference) in a pivotal Phase 3 trial after Phase 2 results showed its “pretty profound” benefit at the lowest tested dose. At ACC 26, Merck Chief Medical Officer Eliav shared that the company is leaning toward a lower dose in the Phase 3 program, aiming to preserve efficacy while optimizing the regimen. The update highlights how dose-finding readouts are being used to shape late-stage trial design for late-line cardiovascular therapies. For biopharma stakeholders, it underscores the practical leverage of Phase 2 dose-performance signals when planning registration-enabling studies. Merck’s next steps will depend on confirming the dose selection across a larger, more definitive patient population in Phase 3.